Esophagogastric junction outflow obstruction: Characterization of a new entity? Clinical, manometric, and neuroimmunological description
Objective To determine the differences between clinical, manometric, and neuroimmunological profile of esophagogastric junction outflow obstruction (EGJOO) and achalasia patients. Methods Seven EGJOO and 27 achalasia patients were enrolled in a blind cross‐sectional study. Peripheral blood (PB) of 1...
Gespeichert in:
| Veröffentlicht in: | Neurogastroenterology and motility 2020-08, Vol.32 (8), p.e13867-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 8 |
| container_start_page | e13867 |
| container_title | Neurogastroenterology and motility |
| container_volume | 32 |
| creator | Furuzawa‐Carballeda, Janette Coss‐Adame, Enrique Romero‐Hernández, Fernanda Zúñiga, Joaquín Uribe‐Uribe, Norma Aguilar‐León, Diana Valdovinos, Miguel A. Núñez‐Álvarez, Carlos A. Hernández‐Ramírez, Diego F. Olivares‐Martínez, Elizabeth Cruz‐Lagunas, Alfredo López‐Verdugo, Fidel Priego‐Ranero, Ángel Azamar‐Llamas, Daniel Rodríguez‐Garcés, Angélica Chávez‐Fernández, Raúl Torres‐Villalobos, Gonzalo |
| description | Objective
To determine the differences between clinical, manometric, and neuroimmunological profile of esophagogastric junction outflow obstruction (EGJOO) and achalasia patients.
Methods
Seven EGJOO and 27 achalasia patients were enrolled in a blind cross‐sectional study. Peripheral blood (PB) of 10 healthy donors and 10 lower esophageal sphincter (LES) muscle biopsies from organ transplant donors were included as controls. The presence of ganglion cells, cells of Cajal, Th22/Th7/Th2/Th1/Tregs/Bregs/pDCregs in tissue, and PB was assessed by immunohistochemistry and flow cytometry. Serum concentration of IL‐22/IL‐17A/IL‐17F/IL‐4/IFN‐γ/IL‐1β/IL‐6/IL‐23/IL‐33/TNF‐α/IL‐10 was determined using bioplex plates. ANAs and antineuronal antibodies were evaluated by immunofluorescence and Western blot.
Key Results
EGJOO and achalasia patients had lower ganglion cells and cells of Cajal percentage vs. controls, while fibrosis was present only in achalasia patients. EGJOO and controls had lower cell percentage of Th22/Th17/Th2 vs. achalasia. EGJOO tissue had lower Th1/Treg cell number vs. achalasia, but higher levels vs. control group. Bregs and pDCregs percentage was higher in EGJOO vs. control group. Percentage of PB subpopulations in EGJOO was not significantly different from control group. Serum cytokine levels were higher for IL‐1β/IL‐6/TNF‐α, while IL‐17A levels were lower in EGJOO vs. achalasia and control group. EGJOO group was negative for ANAs, while in achalasia group, 54% were positive. GAD65 and PNMa/Ta2 antibodies were present in achalasia, whereas Yo and recoverin were positive in EGJOO group.
Conclusions and Inferences
Although EGJOO shares some clinical characteristics with achalasia, the neuroimmunological profile is completely different, suggesting that EGJOO might be a different entity.
Hypothetical model of EGJOO neuroimmunological pathophysiology. |
| doi_str_mv | 10.1111/nmo.13867 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2398616306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2398616306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4197-e9da03864884185966c0a431b2b610de93bb3a47369d2f8aaecb79d37ee009fc3</originalsourceid><addsrcrecordid>eNp10ctq3DAUBmBRUpo07SIvEATZpBAnutiylU0oQ3qBXDbtWsjy8USDLU0li2H6BH3synHaRaHaSEgfP0f8CJ1QcknzunKjv6S8EfUrdES5qAomG3YwnytSUMmqQ_Q2xg0hRLBSvEGHnHHRNGV1hH7dRr990mu_1nEK1uBNcmay3mGfpn7wO-zb_JCe767x6kkHbSYI9qdeVI81drDD4CY77W_warDOGj1c4FE7P8IceoG167JKwdtxTM4Pfj0b3EE0wW7npHfoda-HCO9f9mP0_dPtt9WX4u7x89fVx7vClFTWBchOk_zVMo9Pm0oKYYguOW1ZKyjpQPK25bqsuZAd6xutwbS17HgNQIjsDT9G50vuNvgfCeKkRhsNDIN24FNUjMtGUMGJyPTsH7rxKbg8nWIlq2opazmrD4sywccYoFfbYEcd9ooSNdejcj3quZ5sT18SUztC91f-6SODqwXs7AD7_yeph_vHJfI3IHScaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425799796</pqid></control><display><type>article</type><title>Esophagogastric junction outflow obstruction: Characterization of a new entity? Clinical, manometric, and neuroimmunological description</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Furuzawa‐Carballeda, Janette ; Coss‐Adame, Enrique ; Romero‐Hernández, Fernanda ; Zúñiga, Joaquín ; Uribe‐Uribe, Norma ; Aguilar‐León, Diana ; Valdovinos, Miguel A. ; Núñez‐Álvarez, Carlos A. ; Hernández‐Ramírez, Diego F. ; Olivares‐Martínez, Elizabeth ; Cruz‐Lagunas, Alfredo ; López‐Verdugo, Fidel ; Priego‐Ranero, Ángel ; Azamar‐Llamas, Daniel ; Rodríguez‐Garcés, Angélica ; Chávez‐Fernández, Raúl ; Torres‐Villalobos, Gonzalo</creator><creatorcontrib>Furuzawa‐Carballeda, Janette ; Coss‐Adame, Enrique ; Romero‐Hernández, Fernanda ; Zúñiga, Joaquín ; Uribe‐Uribe, Norma ; Aguilar‐León, Diana ; Valdovinos, Miguel A. ; Núñez‐Álvarez, Carlos A. ; Hernández‐Ramírez, Diego F. ; Olivares‐Martínez, Elizabeth ; Cruz‐Lagunas, Alfredo ; López‐Verdugo, Fidel ; Priego‐Ranero, Ángel ; Azamar‐Llamas, Daniel ; Rodríguez‐Garcés, Angélica ; Chávez‐Fernández, Raúl ; Torres‐Villalobos, Gonzalo</creatorcontrib><description>Objective
To determine the differences between clinical, manometric, and neuroimmunological profile of esophagogastric junction outflow obstruction (EGJOO) and achalasia patients.
Methods
Seven EGJOO and 27 achalasia patients were enrolled in a blind cross‐sectional study. Peripheral blood (PB) of 10 healthy donors and 10 lower esophageal sphincter (LES) muscle biopsies from organ transplant donors were included as controls. The presence of ganglion cells, cells of Cajal, Th22/Th7/Th2/Th1/Tregs/Bregs/pDCregs in tissue, and PB was assessed by immunohistochemistry and flow cytometry. Serum concentration of IL‐22/IL‐17A/IL‐17F/IL‐4/IFN‐γ/IL‐1β/IL‐6/IL‐23/IL‐33/TNF‐α/IL‐10 was determined using bioplex plates. ANAs and antineuronal antibodies were evaluated by immunofluorescence and Western blot.
Key Results
EGJOO and achalasia patients had lower ganglion cells and cells of Cajal percentage vs. controls, while fibrosis was present only in achalasia patients. EGJOO and controls had lower cell percentage of Th22/Th17/Th2 vs. achalasia. EGJOO tissue had lower Th1/Treg cell number vs. achalasia, but higher levels vs. control group. Bregs and pDCregs percentage was higher in EGJOO vs. control group. Percentage of PB subpopulations in EGJOO was not significantly different from control group. Serum cytokine levels were higher for IL‐1β/IL‐6/TNF‐α, while IL‐17A levels were lower in EGJOO vs. achalasia and control group. EGJOO group was negative for ANAs, while in achalasia group, 54% were positive. GAD65 and PNMa/Ta2 antibodies were present in achalasia, whereas Yo and recoverin were positive in EGJOO group.
Conclusions and Inferences
Although EGJOO shares some clinical characteristics with achalasia, the neuroimmunological profile is completely different, suggesting that EGJOO might be a different entity.
Hypothetical model of EGJOO neuroimmunological pathophysiology.</description><identifier>ISSN: 1350-1925</identifier><identifier>EISSN: 1365-2982</identifier><identifier>DOI: 10.1111/nmo.13867</identifier><identifier>PMID: 32368845</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Achalasia ; ANAs ; Antibodies ; antineuronal antibodies ; CD4 effector T cells ; CD8 effector T cells ; Cell number ; Esophageal sphincter ; esophagogastric junction outflow obstruction ; Esophagus ; Fibrosis ; Flow cytometry ; Ganglion cells ; Helper cells ; Immunofluorescence ; Immunohistochemistry ; Interferon ; Lymphocytes T ; myenteric interstitial cells of Cajal ; Peripheral blood ; Recoverin ; regulatory cells ; Sphincter ; Tumor necrosis factor</subject><ispartof>Neurogastroenterology and motility, 2020-08, Vol.32 (8), p.e13867-n/a</ispartof><rights>2020 John Wiley & Sons Ltd</rights><rights>2020 John Wiley & Sons Ltd.</rights><rights>Copyright © 2020 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4197-e9da03864884185966c0a431b2b610de93bb3a47369d2f8aaecb79d37ee009fc3</citedby><cites>FETCH-LOGICAL-c4197-e9da03864884185966c0a431b2b610de93bb3a47369d2f8aaecb79d37ee009fc3</cites><orcidid>0000-0002-0466-5857 ; 0000-0001-5804-7221</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fnmo.13867$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fnmo.13867$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32368845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Furuzawa‐Carballeda, Janette</creatorcontrib><creatorcontrib>Coss‐Adame, Enrique</creatorcontrib><creatorcontrib>Romero‐Hernández, Fernanda</creatorcontrib><creatorcontrib>Zúñiga, Joaquín</creatorcontrib><creatorcontrib>Uribe‐Uribe, Norma</creatorcontrib><creatorcontrib>Aguilar‐León, Diana</creatorcontrib><creatorcontrib>Valdovinos, Miguel A.</creatorcontrib><creatorcontrib>Núñez‐Álvarez, Carlos A.</creatorcontrib><creatorcontrib>Hernández‐Ramírez, Diego F.</creatorcontrib><creatorcontrib>Olivares‐Martínez, Elizabeth</creatorcontrib><creatorcontrib>Cruz‐Lagunas, Alfredo</creatorcontrib><creatorcontrib>López‐Verdugo, Fidel</creatorcontrib><creatorcontrib>Priego‐Ranero, Ángel</creatorcontrib><creatorcontrib>Azamar‐Llamas, Daniel</creatorcontrib><creatorcontrib>Rodríguez‐Garcés, Angélica</creatorcontrib><creatorcontrib>Chávez‐Fernández, Raúl</creatorcontrib><creatorcontrib>Torres‐Villalobos, Gonzalo</creatorcontrib><title>Esophagogastric junction outflow obstruction: Characterization of a new entity? Clinical, manometric, and neuroimmunological description</title><title>Neurogastroenterology and motility</title><addtitle>Neurogastroenterol Motil</addtitle><description>Objective
To determine the differences between clinical, manometric, and neuroimmunological profile of esophagogastric junction outflow obstruction (EGJOO) and achalasia patients.
Methods
Seven EGJOO and 27 achalasia patients were enrolled in a blind cross‐sectional study. Peripheral blood (PB) of 10 healthy donors and 10 lower esophageal sphincter (LES) muscle biopsies from organ transplant donors were included as controls. The presence of ganglion cells, cells of Cajal, Th22/Th7/Th2/Th1/Tregs/Bregs/pDCregs in tissue, and PB was assessed by immunohistochemistry and flow cytometry. Serum concentration of IL‐22/IL‐17A/IL‐17F/IL‐4/IFN‐γ/IL‐1β/IL‐6/IL‐23/IL‐33/TNF‐α/IL‐10 was determined using bioplex plates. ANAs and antineuronal antibodies were evaluated by immunofluorescence and Western blot.
Key Results
EGJOO and achalasia patients had lower ganglion cells and cells of Cajal percentage vs. controls, while fibrosis was present only in achalasia patients. EGJOO and controls had lower cell percentage of Th22/Th17/Th2 vs. achalasia. EGJOO tissue had lower Th1/Treg cell number vs. achalasia, but higher levels vs. control group. Bregs and pDCregs percentage was higher in EGJOO vs. control group. Percentage of PB subpopulations in EGJOO was not significantly different from control group. Serum cytokine levels were higher for IL‐1β/IL‐6/TNF‐α, while IL‐17A levels were lower in EGJOO vs. achalasia and control group. EGJOO group was negative for ANAs, while in achalasia group, 54% were positive. GAD65 and PNMa/Ta2 antibodies were present in achalasia, whereas Yo and recoverin were positive in EGJOO group.
Conclusions and Inferences
Although EGJOO shares some clinical characteristics with achalasia, the neuroimmunological profile is completely different, suggesting that EGJOO might be a different entity.
Hypothetical model of EGJOO neuroimmunological pathophysiology.</description><subject>Achalasia</subject><subject>ANAs</subject><subject>Antibodies</subject><subject>antineuronal antibodies</subject><subject>CD4 effector T cells</subject><subject>CD8 effector T cells</subject><subject>Cell number</subject><subject>Esophageal sphincter</subject><subject>esophagogastric junction outflow obstruction</subject><subject>Esophagus</subject><subject>Fibrosis</subject><subject>Flow cytometry</subject><subject>Ganglion cells</subject><subject>Helper cells</subject><subject>Immunofluorescence</subject><subject>Immunohistochemistry</subject><subject>Interferon</subject><subject>Lymphocytes T</subject><subject>myenteric interstitial cells of Cajal</subject><subject>Peripheral blood</subject><subject>Recoverin</subject><subject>regulatory cells</subject><subject>Sphincter</subject><subject>Tumor necrosis factor</subject><issn>1350-1925</issn><issn>1365-2982</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp10ctq3DAUBmBRUpo07SIvEATZpBAnutiylU0oQ3qBXDbtWsjy8USDLU0li2H6BH3synHaRaHaSEgfP0f8CJ1QcknzunKjv6S8EfUrdES5qAomG3YwnytSUMmqQ_Q2xg0hRLBSvEGHnHHRNGV1hH7dRr990mu_1nEK1uBNcmay3mGfpn7wO-zb_JCe767x6kkHbSYI9qdeVI81drDD4CY77W_warDOGj1c4FE7P8IceoG167JKwdtxTM4Pfj0b3EE0wW7npHfoda-HCO9f9mP0_dPtt9WX4u7x89fVx7vClFTWBchOk_zVMo9Pm0oKYYguOW1ZKyjpQPK25bqsuZAd6xutwbS17HgNQIjsDT9G50vuNvgfCeKkRhsNDIN24FNUjMtGUMGJyPTsH7rxKbg8nWIlq2opazmrD4sywccYoFfbYEcd9ooSNdejcj3quZ5sT18SUztC91f-6SODqwXs7AD7_yeph_vHJfI3IHScaQ</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Furuzawa‐Carballeda, Janette</creator><creator>Coss‐Adame, Enrique</creator><creator>Romero‐Hernández, Fernanda</creator><creator>Zúñiga, Joaquín</creator><creator>Uribe‐Uribe, Norma</creator><creator>Aguilar‐León, Diana</creator><creator>Valdovinos, Miguel A.</creator><creator>Núñez‐Álvarez, Carlos A.</creator><creator>Hernández‐Ramírez, Diego F.</creator><creator>Olivares‐Martínez, Elizabeth</creator><creator>Cruz‐Lagunas, Alfredo</creator><creator>López‐Verdugo, Fidel</creator><creator>Priego‐Ranero, Ángel</creator><creator>Azamar‐Llamas, Daniel</creator><creator>Rodríguez‐Garcés, Angélica</creator><creator>Chávez‐Fernández, Raúl</creator><creator>Torres‐Villalobos, Gonzalo</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0466-5857</orcidid><orcidid>https://orcid.org/0000-0001-5804-7221</orcidid></search><sort><creationdate>202008</creationdate><title>Esophagogastric junction outflow obstruction: Characterization of a new entity? Clinical, manometric, and neuroimmunological description</title><author>Furuzawa‐Carballeda, Janette ; Coss‐Adame, Enrique ; Romero‐Hernández, Fernanda ; Zúñiga, Joaquín ; Uribe‐Uribe, Norma ; Aguilar‐León, Diana ; Valdovinos, Miguel A. ; Núñez‐Álvarez, Carlos A. ; Hernández‐Ramírez, Diego F. ; Olivares‐Martínez, Elizabeth ; Cruz‐Lagunas, Alfredo ; López‐Verdugo, Fidel ; Priego‐Ranero, Ángel ; Azamar‐Llamas, Daniel ; Rodríguez‐Garcés, Angélica ; Chávez‐Fernández, Raúl ; Torres‐Villalobos, Gonzalo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4197-e9da03864884185966c0a431b2b610de93bb3a47369d2f8aaecb79d37ee009fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Achalasia</topic><topic>ANAs</topic><topic>Antibodies</topic><topic>antineuronal antibodies</topic><topic>CD4 effector T cells</topic><topic>CD8 effector T cells</topic><topic>Cell number</topic><topic>Esophageal sphincter</topic><topic>esophagogastric junction outflow obstruction</topic><topic>Esophagus</topic><topic>Fibrosis</topic><topic>Flow cytometry</topic><topic>Ganglion cells</topic><topic>Helper cells</topic><topic>Immunofluorescence</topic><topic>Immunohistochemistry</topic><topic>Interferon</topic><topic>Lymphocytes T</topic><topic>myenteric interstitial cells of Cajal</topic><topic>Peripheral blood</topic><topic>Recoverin</topic><topic>regulatory cells</topic><topic>Sphincter</topic><topic>Tumor necrosis factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furuzawa‐Carballeda, Janette</creatorcontrib><creatorcontrib>Coss‐Adame, Enrique</creatorcontrib><creatorcontrib>Romero‐Hernández, Fernanda</creatorcontrib><creatorcontrib>Zúñiga, Joaquín</creatorcontrib><creatorcontrib>Uribe‐Uribe, Norma</creatorcontrib><creatorcontrib>Aguilar‐León, Diana</creatorcontrib><creatorcontrib>Valdovinos, Miguel A.</creatorcontrib><creatorcontrib>Núñez‐Álvarez, Carlos A.</creatorcontrib><creatorcontrib>Hernández‐Ramírez, Diego F.</creatorcontrib><creatorcontrib>Olivares‐Martínez, Elizabeth</creatorcontrib><creatorcontrib>Cruz‐Lagunas, Alfredo</creatorcontrib><creatorcontrib>López‐Verdugo, Fidel</creatorcontrib><creatorcontrib>Priego‐Ranero, Ángel</creatorcontrib><creatorcontrib>Azamar‐Llamas, Daniel</creatorcontrib><creatorcontrib>Rodríguez‐Garcés, Angélica</creatorcontrib><creatorcontrib>Chávez‐Fernández, Raúl</creatorcontrib><creatorcontrib>Torres‐Villalobos, Gonzalo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neurogastroenterology and motility</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furuzawa‐Carballeda, Janette</au><au>Coss‐Adame, Enrique</au><au>Romero‐Hernández, Fernanda</au><au>Zúñiga, Joaquín</au><au>Uribe‐Uribe, Norma</au><au>Aguilar‐León, Diana</au><au>Valdovinos, Miguel A.</au><au>Núñez‐Álvarez, Carlos A.</au><au>Hernández‐Ramírez, Diego F.</au><au>Olivares‐Martínez, Elizabeth</au><au>Cruz‐Lagunas, Alfredo</au><au>López‐Verdugo, Fidel</au><au>Priego‐Ranero, Ángel</au><au>Azamar‐Llamas, Daniel</au><au>Rodríguez‐Garcés, Angélica</au><au>Chávez‐Fernández, Raúl</au><au>Torres‐Villalobos, Gonzalo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Esophagogastric junction outflow obstruction: Characterization of a new entity? Clinical, manometric, and neuroimmunological description</atitle><jtitle>Neurogastroenterology and motility</jtitle><addtitle>Neurogastroenterol Motil</addtitle><date>2020-08</date><risdate>2020</risdate><volume>32</volume><issue>8</issue><spage>e13867</spage><epage>n/a</epage><pages>e13867-n/a</pages><issn>1350-1925</issn><eissn>1365-2982</eissn><abstract>Objective
To determine the differences between clinical, manometric, and neuroimmunological profile of esophagogastric junction outflow obstruction (EGJOO) and achalasia patients.
Methods
Seven EGJOO and 27 achalasia patients were enrolled in a blind cross‐sectional study. Peripheral blood (PB) of 10 healthy donors and 10 lower esophageal sphincter (LES) muscle biopsies from organ transplant donors were included as controls. The presence of ganglion cells, cells of Cajal, Th22/Th7/Th2/Th1/Tregs/Bregs/pDCregs in tissue, and PB was assessed by immunohistochemistry and flow cytometry. Serum concentration of IL‐22/IL‐17A/IL‐17F/IL‐4/IFN‐γ/IL‐1β/IL‐6/IL‐23/IL‐33/TNF‐α/IL‐10 was determined using bioplex plates. ANAs and antineuronal antibodies were evaluated by immunofluorescence and Western blot.
Key Results
EGJOO and achalasia patients had lower ganglion cells and cells of Cajal percentage vs. controls, while fibrosis was present only in achalasia patients. EGJOO and controls had lower cell percentage of Th22/Th17/Th2 vs. achalasia. EGJOO tissue had lower Th1/Treg cell number vs. achalasia, but higher levels vs. control group. Bregs and pDCregs percentage was higher in EGJOO vs. control group. Percentage of PB subpopulations in EGJOO was not significantly different from control group. Serum cytokine levels were higher for IL‐1β/IL‐6/TNF‐α, while IL‐17A levels were lower in EGJOO vs. achalasia and control group. EGJOO group was negative for ANAs, while in achalasia group, 54% were positive. GAD65 and PNMa/Ta2 antibodies were present in achalasia, whereas Yo and recoverin were positive in EGJOO group.
Conclusions and Inferences
Although EGJOO shares some clinical characteristics with achalasia, the neuroimmunological profile is completely different, suggesting that EGJOO might be a different entity.
Hypothetical model of EGJOO neuroimmunological pathophysiology.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32368845</pmid><doi>10.1111/nmo.13867</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0002-0466-5857</orcidid><orcidid>https://orcid.org/0000-0001-5804-7221</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1350-1925 |
| ispartof | Neurogastroenterology and motility, 2020-08, Vol.32 (8), p.e13867-n/a |
| issn | 1350-1925 1365-2982 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2398616306 |
| source | Wiley Free Content; Wiley Online Library Journals Frontfile Complete |
| subjects | Achalasia ANAs Antibodies antineuronal antibodies CD4 effector T cells CD8 effector T cells Cell number Esophageal sphincter esophagogastric junction outflow obstruction Esophagus Fibrosis Flow cytometry Ganglion cells Helper cells Immunofluorescence Immunohistochemistry Interferon Lymphocytes T myenteric interstitial cells of Cajal Peripheral blood Recoverin regulatory cells Sphincter Tumor necrosis factor |
| title | Esophagogastric junction outflow obstruction: Characterization of a new entity? Clinical, manometric, and neuroimmunological description |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T23%3A07%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Esophagogastric%20junction%20outflow%20obstruction:%20Characterization%20of%20a%20new%20entity?%20Clinical,%20manometric,%20and%20neuroimmunological%20description&rft.jtitle=Neurogastroenterology%20and%20motility&rft.au=Furuzawa%E2%80%90Carballeda,%20Janette&rft.date=2020-08&rft.volume=32&rft.issue=8&rft.spage=e13867&rft.epage=n/a&rft.pages=e13867-n/a&rft.issn=1350-1925&rft.eissn=1365-2982&rft_id=info:doi/10.1111/nmo.13867&rft_dat=%3Cproquest_cross%3E2398616306%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425799796&rft_id=info:pmid/32368845&rfr_iscdi=true |